What is the pathophysiology of myxedema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathophysiology of Myxedema

Myxedema results from severe thyroid hormone deficiency leading to the interstitial deposition of hydrophilic mucopolysaccharides (glycosaminoglycans), which causes fluid retention and creates what is essentially a lymphatic edema.

Core Pathophysiological Mechanism

The fundamental problem in myxedema is low intracellular T3 (triiodothyronine), which triggers a cascade of metabolic and structural derangements 1, 2:

Primary Direct Effects of Thyroid Hormone Deficiency

  • Mucopolysaccharide accumulation: The hallmark pathological feature is deposition of hydrophilic mucopolysaccharides in the interstitial spaces, which bind water and create the characteristic non-pitting edema 1
  • Metabolic suppression: Reduced cellular metabolism affects all organ systems, with decreased metabolic rate despite often suppressed appetite 3
  • Impaired protein metabolism: Thyroid hormone deficiency interferes with metabolism of interstitial matrix compounds, cell surface proteins, and intracellular microfilament proteins 1

Secondary Cardiovascular and Renal Consequences

The cardiovascular and renal systems undergo significant derangements that perpetuate the edematous state:

  • Impaired lymphatic drainage: The mucopolysaccharide deposition directly impairs both blood circulation and lymphatic drainage, making myxedema fundamentally a lymphatic edema 1
  • Reduced cardiac output: Low intracellular T3 leads to cardiogenic shock with hypotension and bradycardia 2
  • Decreased glomerular filtration rate (GFR): This impairs the kidney's capacity for water excretion 1
  • Reduced renal Na,K-ATPase activity: Occurs in specific nephron segments, leading to impaired sodium reabsorption 1

Fluid and Electrolyte Disturbances

The weight gain observed in myxedema is principally due to fluid mobilization rather than true adipose tissue accumulation 3. This was confirmed in studies showing significant weight loss following treatment, primarily from diuresis 3.

  • Hyponatremia: This is an indirect consequence of T3 deficiency, caused by impaired renal sodium reabsorption and reduced GFR—not primarily from inappropriate ADH elevation as commonly believed 1
  • Fluid retention: Results from the combination of mucopolysaccharide-bound water, impaired lymphatic drainage, and reduced renal clearance

Paradoxical Hormetic Response

Interestingly, myxedema can occur in both severe hypothyroidism AND hyperthyroidism (pretibial myxedema in Graves' disease), representing a hormetic-type biphasic response to thyroid hormones 4. In hyperthyroidism, this localized myxedema is caused by poorly understood autoimmune processes rather than hormone deficiency 1.

Clinical Decompensation to Myxedema Coma

When myxedema progresses to myxedema coma, additional pathophysiological factors emerge 2:

  • Respiratory depression: From reduced central respiratory drive
  • Hypothermia: From decreased thermogenesis (though less prominent in tropical climates)
  • Altered mental status/coma: From cerebral hypoperfusion and metabolic derangements
  • Multiorgan dysfunction: Progressive cardiovascular collapse, respiratory failure, and metabolic crisis

Common precipitating factors include infections, discontinuation of thyroid supplements, and exposure to sedative drugs 2. The mortality rate for myxedema coma remains 6.8% even in modern care, representing a 9.92-fold increased risk of death compared to compensated hypothyroidism 5.

Time-Dependent Progression

The development of myxedema follows a time-dependent pattern where gradual physiological adaptation allows patients with chronic hypothyroidism to remain clinically stable until a precipitating event causes acute decompensation 5. This explains why myxedema coma often occurs in patients with long-standing undiagnosed or undertreated hypothyroidism who experience an acute stressor.

References

Research

Myxedema.

Kidney international. Supplement, 1997

Research

Myxedema coma: a new look into an old crisis.

Journal of thyroid research, 2011

Guideline

clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2012

Research

Myxedema in Both Hyperthyroidism and Hypothyroidism: A Hormetic Response?

International journal of molecular sciences, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.